Clinical trial · Observational
Enrollment on the Childhood Cancer Research Network (CCRN) of the Children's Oncology Group
Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The Children's Oncology Group has established a research network, the Childhood Cancer Research Network (CCRN), to collect information about children with cancer and other conditions that are benign but involve abnormal cell growth in order to help doctors and scientists better understand childhood cancer. The CCRN's goal is to collect clinical information about every child diagnosed with cancer and similar conditions in the United States and Canada, to allow researchers to study patterns, characteristics, and causes of childhood cancer. The information can also help researchers study the causes of childhood cancer. To expand the CCRN, parents of children who have been diagnosed with cancer will be asked to provide information about themselves and their child for research purposes.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Tumors | Brain Neoplasm | ALIAS | 0.90 |
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Pediatric Cancer | Childhood Malignant Neoplasm | ALIAS | 0.90 |
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To collect information on children with cancer
- timeFrame
- After initial diagnosis
Secondary outcomes (1)
- measure
- To obtain consent to contact in the future for participation in future clinical trials
- timeFrame
- At enrollment and at age of majority
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 21 Years
Show eligibility criteria text
* All patients, diagnosed with a primary malignancy since the date the initial IRB approval was received for this study with any of the following diagnoses are eligible: * All cancer cases with an ICD-O histologic behavior code of two "2" (carcinoma in situ) or three "3" (malignant). * All lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant. * The benign/borderline conditions which will be reportable by agreement shall include: * Mesoblastic nephroma. * All teratomas, regardless of locations. * Myeloproliferative disease * Langerhans Cell histiocytosis * Patients with a secondary malignancy may be eligible provided they also meet the criteria in the above. These patients need to be enrolled using their primary diagnosis. * Participants 0 through 21 years of age are eligible; irrespective of eligibility for other COG studies. * Participant must be resident of the United States, Canada or Mexico.
References
Publications (1)
- BACKGROUNDRoss JA, Severson RK, Pollock BH, Robison LL. Childhood cancer in the United States. A geographical analysis of cases from the Pediatric Cooperative Clinical Trials groups. Cancer. 1996 Jan 1;77(1):201-7. doi: 10.1002/(SICI)1097-0142(19960101)77:13.0.CO;2-7. PMID 8630931